Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AVBP 
ArriVent BioPharma, Inc. Common Stock (AVBP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: AVBP (1-star) is a SELL. SELL since 3 days. Simulated Profits (3.63%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40.23
1 Year Target Price $40.23
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.58% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 906.95M USD | Price to earnings Ratio - | 1Y Target Price 40.23 |
Price to earnings Ratio - | 1Y Target Price 40.23 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 15.47 - 29.71 | Updated Date 12/29/2025 |
52 Weeks Range 15.47 - 29.71 | Updated Date 12/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.78% | Return on Equity (TTM) -51.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 606741501 | Price to Sales(TTM) - |
Enterprise Value 606741501 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 41281361 | Shares Floating 22710941 |
Shares Outstanding 41281361 | Shares Floating 22710941 | ||
Percent Insiders 8.1 | Percent Institutions 99.04 |
Upturn AI SWOT
ArriVent BioPharma, Inc. Common Stock
Company Overview
History and Background
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for respiratory diseases. The company was founded with the aim of addressing unmet medical needs in conditions like asthma and COPD. Significant milestones include advancing its lead drug candidate into clinical trials and securing funding to support ongoing development.
Core Business Areas
- Respiratory Disease Therapeutics: Development and commercialization of novel drug candidates targeting the underlying mechanisms of severe respiratory diseases, including severe asthma and chronic obstructive pulmonary disease (COPD).
Leadership and Structure
Information regarding ArriVent BioPharma, Inc.'s current leadership team and detailed organizational structure is not readily available in the public domain as it is a relatively nascent company. This typically includes a CEO, CFO, Chief Medical Officer, and a Board of Directors overseeing strategic decisions.
Top Products and Market Share
Key Offerings
- AVP-101: AVP-101 is ArriVent's lead drug candidate, a novel inhaled therapy designed to treat severe asthma. It targets a specific inflammatory pathway. Market share data is not yet applicable as the product is in clinical development. Key competitors in the severe asthma market include products from companies like AstraZeneca, GSK, and Regeneron.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the respiratory disease sector, is characterized by significant unmet medical needs, ongoing research and development, and a complex regulatory landscape. The market is driven by increasing prevalence of chronic respiratory conditions and demand for more effective and targeted treatments.
Positioning
ArriVent BioPharma is positioned as an emerging player in the biopharmaceutical space, aiming to carve out a niche in the severe respiratory disease market with its innovative therapeutic approach. Its competitive advantage lies in its novel mechanism of action for its lead candidate.
Total Addressable Market (TAM)
The total addressable market for severe respiratory diseases is substantial, with billions of dollars spent annually on treatments. ArriVent BioPharma's positioning is focused on capturing a segment of this market with its specialized therapies, aiming for a significant share as its products progress through development and commercialization.
Upturn SWOT Analysis
Strengths
- Innovative drug candidate with a novel mechanism of action.
- Focus on a significant unmet medical need in respiratory diseases.
- Experienced scientific and management team (assumed, typical for biotech).
Weaknesses
- Clinical-stage company with no approved products.
- Dependence on successful clinical trial outcomes.
- Limited historical financial performance and market presence.
- Need for substantial future funding.
Opportunities
- Growing prevalence of severe respiratory diseases.
- Potential for strategic partnerships or acquisitions.
- Advancements in drug delivery technologies.
- Expansions into other respiratory indications.
Threats
- Clinical trial failures or delays.
- Regulatory hurdles and approval challenges.
- Intense competition from established pharmaceutical companies.
- Pricing pressures and reimbursement challenges.
- Patent expirations for existing therapies.
Competitors and Market Share
Key Competitors
- AstraZeneca (AZN)
- GlaxoSmithKline (GSK)
- Regeneron Pharmaceuticals (REGN)
Competitive Landscape
ArriVent BioPharma faces strong competition from established players with approved therapies for severe asthma and COPD. Its advantage lies in its novel approach, but it must overcome the significant hurdles of clinical development and gain market acceptance against incumbents with proven track records and extensive marketing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for ArriVent BioPharma, Inc. would be primarily measured by its progress in clinical development, fundraising milestones, and strategic advancements, rather than traditional revenue growth.
Future Projections: Future growth projections for ArriVent BioPharma, Inc. are highly dependent on the successful clinical development and regulatory approval of its pipeline. Analyst estimates would focus on potential peak sales of its lead candidate and overall market penetration.
Recent Initiatives: Recent initiatives likely include progressing its lead drug candidate (AVP-101) through clinical trials, seeking additional funding rounds, and potentially exploring strategic partnerships.
Summary
ArriVent BioPharma, Inc. is a biopharmaceutical company with a promising lead candidate for severe respiratory diseases. Its strengths lie in its innovative approach and focus on unmet needs. However, it faces significant weaknesses as a clinical-stage entity, with no approved products and a heavy reliance on future funding and successful clinical trials. The company has opportunities for growth but must navigate intense competition and regulatory challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company public filings (if available)
- Biopharmaceutical industry reports
- Financial news and analysis sites
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. The biopharmaceutical industry is inherently risky, and ArriVent BioPharma, Inc. is a clinical-stage company with significant uncertainties. Investors should conduct their own due diligence and consult with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ArriVent BioPharma, Inc. Common Stock
Exchange NASDAQ | Headquaters Newtown Square, PA, United States | ||
IPO Launch date 2024-01-26 | Co-Founder, Chairman, President & CEO Dr. Zhengbin Yao Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://arrivent.com |
Full time employees 52 | Website https://arrivent.com | ||
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.